Eli Lilly and Company's shares were up 7% this morning on guidance that they are seriously ramping up their production capacity for their obesity and diabetes drugs, Mounjaro and Trulicity. They also increase their revenue forecast by $2B this year! We already know that diabetes drugs like Ozempic have become very mainstream and the drug companies are all making huge profits, but the question is, can the average consumer or aspiring founder benefit from this craze? The answer is yes. I've shared my POV time and time again that I think that drugs like Ozempic are going to have a massive impact on the global economy for the foreseeable future. I break down how I would approach capitalizing on the whitespace Ozempic is generating because this is truly a once in a life time opportunity. #startup #entrepreneur #ozempic #diabetes #weightloss
This is SUCH incredible tactical advice. Indeed, one of the reasons Michelle Goad and I put GLP-1 drugs like Ozempic in our Brand Yearbook this year is because it represents such a massive opportunity and will be so disruptive to other consumer categories 🙌
Oh yes these misused drugs are going to be paydirt for those companies mopping up all the hideous medical fallout to come
Am I wrong in assuming I don’t think the solution to curing medication side effects is with the use of more supplements? Couldn’t those “pain killer type solutions” lead to more side effects which leaves the consumer in a never ending search to alleviate symptoms?
Not to mention that the majority of weight your losing is muscle…. The human body is very intelligent and will start to adapt to only getting the low number of calories it’s receiving. People will put the weight back on. It’s all statistically proven.
What I’m more Interested in is solving the issues that lead people to becoming over weight. These “quick fixes” aren’t the answer. If they stop taking these drugs they’ll end up in the same situation. You have to change the relationship to food.
Very interesting, where can we find your report?
Junk drugs causing more illness and plenty of profits
Very clear thinking. Loved this.
CFO @ Kate Farms | Strategic Growth Architect | Scaling and Building Value for Consumer Health & Wellness Brands | ex-Oura, Sonos, Morgan Stanley
2moThis is a fantastic blueprint. There is a lot of whitespace here, and it's likely startups are going to stumble a bit until reliable trends emerge. I recently put together a slide carousel on GLP-1 impact on consumer behavior: https://www.linkedin.com/posts/danielwelch_impact-of-glp-1-usage-on-consumer-health-activity-7162893052502552576-MnZY?utm_source=share&utm_medium=member_desktop